GlassScriptPhysician profile
Jon R Uyesaka
NPI 1801958525
$8,822.02
in general payments reported to CMS, 2019-2025
39 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $1,037 · 2021: $1,484 · 2022: $1,369 · 2023: $1,149 · 2024: $1,148 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,238.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,212.49 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $923.57 | 2019-2025 | |
| Novo Nordisk INC | $914.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $574.30 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.28 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $312.97 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $271.22 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $270.38 | 2019-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $268.77 | 2022-2025 | |
| Portola Pharmaceuticals, LLC | $199.54 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $193.09 | 2021-2023 | |
| Amarin Pharma, INC. | $189.57 | 2019-2021 | |
| Astellas Pharma US INC | $188.23 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $183.02 | 2023-2025 | Cologuard Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Uyesaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.